Ignite Creation Date:
2025-12-25 @ 12:01 AM
Ignite Modification Date:
2026-01-06 @ 3:08 AM
Study NCT ID:
NCT06708858
Status:
RECRUITING
Last Update Posted:
2024-11-27
First Post:
2024-11-11
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Phase Ⅱ Clinical Study of Surufatinib Combined With Gemcitabine and Cisplatin Plus Durvalumab/Pembrolizumab Regimen in the Treatment of Advanced Biliary Tract Cancer
Sponsor:
Dai, Guanghai
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
A2024-BTC-01
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR_INVESTIGATOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None